Cathie Wood has never been one to follow the crowd. But her latest moves represent something more than contrarianism. They signal a fundamental rethinking of where innovation-driven returns will come from over the next decade — and a willingness to walk away from some of the most profitable trades of the past five years.
The ARK Invest founder has been systematically selling out of mega-cap technology stocks, reducing her funds’ exposure to the very companies that have powered the market’s historic rally since late 2022. Apple, Alphabet, Microsoft, Amazon — names that dominate virtually every institutional portfolio in America — are being shown the door at ARK. In their place: Bitcoin-linked equities, artificial intelligence infrastructure plays, genomics companies, and a handful of smaller, high-conviction bets that most traditional asset managers wouldn’t touch.
It’s a bold repositioning. And it’s happening at a moment when the consensus on Wall Street has never been more aligned behind big tech.
The Great Rotation Out of Mega-Caps
According to Yahoo Finance, Wood’s ARK Innovation ETF (ARKK) has been aggressively trimming positions in large-cap technology names throughout 2024 and into 2025. The fund, which manages billions in assets and became a household name during the pandemic-era growth stock frenzy, has been reallocating capital away from the so-called Magnificent Seven stocks toward companies Wood believes are undervalued relative to their long-term disruptive potential.
This isn’t a subtle shift. It’s a wholesale strategic pivot.
Wood has been vocal about her reasoning. She argues that mega-cap tech stocks have become overcrowded trades, with valuations that reflect past innovation rather than future breakthroughs. In her view, the market is making a classic mistake — extrapolating the recent past into the indefinite future while ignoring the compounding potential of smaller, less-followed companies operating at the frontier of technological change.
Her critics, and there are many, counter that ARK’s track record since the 2021 peak speaks for itself. ARKK lost roughly 75% of its value from its February 2021 high to its late-2022 low, a drawdown that wiped out most of the gains accumulated during the fund’s meteoric rise. The Magnificent Seven, meanwhile, have continued to deliver. Nvidia alone has returned more than 800% since the start of 2023.
So why is Wood walking away from what’s working?
The answer lies in her investment philosophy, which has always prioritized five-year return expectations over near-term momentum. ARK’s internal research models project that many mega-cap names are priced for mid-single-digit annual returns over the next half-decade, while their preferred holdings — companies like Roku, UiPath, Exact Sciences, Coinbase, and Tempus AI — offer what Wood’s team estimates could be 30% to 50% annualized upside if their disruption theses play out.
Those are enormous claims. They’re also the kind of projections that have made Wood simultaneously one of the most followed and most polarizing figures in asset management.
ARK’s daily trade notifications, which the firm publishes with unusual transparency, have shown consistent selling in names like Alphabet and Apple over recent months. At the same time, the firm has been adding to positions in companies tied to Bitcoin adoption, AI-driven healthcare, autonomous logistics, and next-generation energy storage. The pattern is unmistakable: Wood is concentrating her bets on what she considers the five major innovation platforms of the coming decade — artificial intelligence, robotics, energy storage, blockchain technology, and multiomic sequencing.
That concentration cuts both ways. It’s what produced ARKK’s extraordinary gains in 2020, when the fund returned nearly 150%. And it’s what produced the devastating losses that followed.
Bitcoin, Coinbase, and the Crypto Conviction
Perhaps no position better illustrates Wood’s current thinking than her massive bet on Bitcoin-adjacent equities. Coinbase Global remains one of ARKK’s largest holdings, and ARK has been adding to the position even as the stock has surged more than 50% year-to-date in 2025.
Wood’s Bitcoin thesis is well-documented. She has publicly stated that she believes Bitcoin could reach $1.5 million per coin by 2030, a projection that would represent roughly a 14x increase from current levels. Her reasoning rests on several converging factors: institutional adoption accelerating after the approval of spot Bitcoin ETFs in January 2024, sovereign wealth funds beginning to allocate to digital assets, and Bitcoin’s fixed supply creating asymmetric upside as demand grows.
It’s a thesis that looked fringe three years ago. It looks less so today.
The approval of spot Bitcoin ETFs by the SEC has indeed triggered substantial institutional inflows. BlackRock’s iShares Bitcoin Trust (IBIT) alone has attracted tens of billions in assets, making it one of the most successful ETF launches in history. Bitcoin itself has traded above $100,000 for much of 2025, vindicating early believers — at least for now.
But Wood isn’t just buying Bitcoin exposure for the sake of price appreciation. She sees Coinbase as a platform company that will benefit from the broader financialization of digital assets, including tokenized securities, stablecoins, and decentralized finance applications. ARK’s research suggests that Coinbase’s revenue base could diversify significantly beyond trading commissions over the next several years, reducing the cyclicality that has plagued the stock.
That’s an optimistic read. Coinbase still derives the majority of its revenue from transaction fees, which are highly correlated with crypto market volatility and retail trading activity. The company has made progress on subscription and services revenue, but the transformation Wood envisions is far from complete.
Still, the position reflects something important about how ARK thinks about risk. Where most institutional investors see volatility as a bug, Wood sees it as a feature — a source of mispricing that patient, conviction-driven investors can exploit.
The AI allocation tells a similar story. While most funds have piled into Nvidia, Microsoft, and other large-cap AI beneficiaries, ARK has been building positions in smaller companies that Wood believes will capture disproportionate value as AI moves from infrastructure build-out to application deployment. Tempus AI, which uses machine learning to analyze clinical and molecular data for precision medicine, has become a significant ARKK holding. So has UiPath, the robotic process automation company that Wood sees as a primary beneficiary of enterprise AI adoption.
These aren’t consensus picks. They’re bets on the second and third derivatives of the AI trend — companies that need the broader AI infrastructure to mature before their own growth inflects. It’s a timing bet as much as a technology bet, and timing is where ARK has historically struggled.
The genomics allocation is arguably the most contrarian of all. Companies like Exact Sciences, CRISPR Therapeutics, and Pacific Biosciences have been deeply out of favor since the post-pandemic biotech selloff. Many have seen their share prices decline 60% to 80% from peak levels. Wood has been buying into that weakness, arguing that the convergence of AI and genomic sequencing will unlock breakthroughs in drug discovery, diagnostics, and personalized medicine that the market is dramatically underpricing.
She may be right. The question, as always with ARK, is when.
The Case Against — and the Case For
Wood’s detractors have plenty of ammunition. ARKK’s five-year annualized return still trails the S&P 500 by a wide margin. The fund’s assets under management have shrunk from a peak of roughly $28 billion to a fraction of that, as investors who bought near the top have redeemed shares and moved on. And the opportunity cost of avoiding mega-cap tech during the AI boom has been enormous.
There’s also a structural critique. ARK’s concentrated, high-turnover approach generates significant transaction costs and tax inefficiencies for investors in taxable accounts. The firm’s practice of publishing daily trades, while admirable from a transparency standpoint, also creates front-running risk — other market participants can anticipate ARK’s moves and trade ahead of them, potentially eroding returns.
And then there’s the performance question that won’t go away. Many of ARK’s top holdings from the 2020-2021 era — Zoom, Teladoc, Roku, Block — have never recovered their pandemic-era valuations. Some may never do so. The bull case for these companies often rested on growth trajectories that have since decelerated or failed to materialize entirely.
But dismissing Wood entirely would be a mistake.
Her early calls on Tesla, Bitcoin, and genomics were prescient, even if the timing of entry and exit was imperfect. ARK’s open-source research model has produced genuinely original analysis on topics ranging from autonomous vehicle economics to the cost curves of gene editing. And her willingness to take the other side of crowded trades has, at certain inflection points, generated extraordinary returns for investors who got in at the right time.
The current setup may be one of those inflection points. If mega-cap tech valuations compress — whether due to regulatory pressure, slowing earnings growth, or a rotation into undervalued sectors — the kinds of stocks ARK owns could benefit disproportionately. Small and mid-cap growth stocks have underperformed large caps by historic margins over the past three years. Mean reversion alone could provide a tailwind.
Wood is also making a macro argument that deserves consideration. She has repeatedly warned that deflationary forces — driven by AI-enabled productivity gains, falling energy costs, and demographic shifts — are stronger than most investors appreciate. In a deflationary or disinflationary environment, companies with high revenue growth and improving unit economics tend to outperform, even if they’re not yet profitable. That’s a description that fits many of ARK’s holdings.
Whether the market agrees anytime soon is another matter entirely.
For now, Cathie Wood is doing what she’s always done: making big, concentrated bets on her vision of the future and accepting the volatility that comes with it. She’s selling what everyone else is buying and buying what everyone else is selling. It’s a strategy that has produced both spectacular gains and spectacular losses.
The next few years will determine which side of that ledger her current positioning lands on. But one thing is clear — in an industry increasingly dominated by index-hugging and risk-averse positioning, Wood remains one of the few active managers willing to be genuinely, uncomfortably different.
That’s either her greatest strength or her fatal flaw. Possibly both.
WebProNews is an iEntry Publication